text_1: 在 心血管 终点 方面 , COLCOT 试验 中 秋水仙碱 的 益处 至少 与 CANTOS 试验 中卡纳 单抗 的 益处 同样 大 2 .
  
text_2: the benefits of colchicine with regard to cardiovascular end points in COLCOT were at least as large as those of canakinumab in CANTOS.2
  